From: Impact of a digital web-based asthma platform, a real-life study
Inactive users n = 41 | Active users n = 106 | p-value | |
---|---|---|---|
Age, mean (SD) | 45 (17) | 47 (13) | 0.40 |
Female, n (%) | 33 (80) | 80 (75) | 0.52 |
BMI, mean (SD) | 28.0 (6.2) | 29.1 (7.4) | 0.39 |
Reflux, n (%) | 5 (12) | 31 (29) | 0.034 |
Atopic dermatitis, n (%) | 16 (39) | 26 (25) | 0.081 |
Nasal polyposis, n (%) | 16 (39) | 27 (25) | 0.11 |
CRSwNP/CRSsNP, n (%) | 22 (54) | 58 (55) | 0.91 |
Allergic rhinitis, n (%) | 19 (46) | 48 (45) | 0.91 |
Bronchiectasis, n (%) | 2 (5) | 11 (10) | 0.52 |
Hypertension, n (%) | 9 (22) | 32 (30) | 0.32 |
COPD, n (%) | 1 (2) | 4 (4) | 0.99 |
Diabetes mellitus, n (%) | 2 (5) | 10 (9) | 0.51 |
Coronary artery disease, n (%) | 0 (0) | 1 (1) | 0.99 |
Atrial fibrillation, n (%) | 1 (2) | 4 (4) | 0.98 |
Hypothyroidism, n (%) | 3 (7) | 14 (13) | 0.40 |
Obstructive sleep apnea, n (%) | 4 (10) | 21 (20) | 0.22 |
Osteoporosis/osteopenia, n (%) | 3 (7) | 18 (17) | 0.19 |
Depression, n (%) | 11 (27) | 21 (20) | 0.36 |
Anxiety, n (%) | 4 (10) | 21 (20) | 0.22 |
FEV1 liter, mean (SD) | 2.70 (0.73) | 2.75 (0.81) | 0.73 |
FVC liter, mean (SD) | 3.58 (0.84) | 3.67 (0.87) | 0.60 |
FEV, mean (SD) | 0.75 (0.10) | 0.74 (0.13) | 0.77 |
Smoking status, n (%) | 0.45 | ||
Never smoked | 36 (88) | 82 (77) | |
Ex-smoker | 5 (12) | 23 (22) | |
Smoker | 0 (0) | 1 (1) | |
Positive skin prick test or elevated allergen-specific serum IgE, n (%) | 23 (56) | 64 (64) | 0.38 |
Serum IgE kU/liter, median (IQR) | 84 (32, 306) [31] | 74(23, 283) [82] | 0.65 |
Exhaled NO ppb, mean (SD) | 29.3 (39.8) [14] | 34.1 (34.1) [34] | 0.72 |
Blood eosinophil count E9/liter, mean (SD) | 0.31 (0.31) [23] | 0.21 (0.24) [78] | 0.11 |
ACT, maximal score 25, mean (SD) | 17.2 (5.3) [27] | 17.1 (4.8) [56] | 0.98 |
Daily OCS medication, n (%) | 5 (12) | 22 (21) | 0.23 |
GINA, n (%) | 0.024 | ||
step 1 | 2 (5) | 0 (0) | |
step 2 | 2 (5) | 1 (1) | |
step 3 | 3 (7) | 11 (10) | |
step 4 | 17 (41) | 28 (26) | |
step 5 | 17 (41) | 66 (62) | |
Biological asthma therapy, n (%) | 9 (22) | 28 (26) | 0.58 |